Krieglstein G K
Klin Monbl Augenheilkd. 1978 May;172(5):677-85.
The intraocular pressure response to timolol ophthalmic solution, a beta-adrenergic blocking agent, was tested in two groups of open angle glaucoma patients using the 0,1% and the 0,5% solution. The 0.5% concentration gave a mean IOP reduction of 13 mm Hg in 39 glaucomatous eyes, corresponding to 46% of the pretreatment pressure level. The 0,1% concentration resulted in an average pressure decrease of 11,5 mm Hg in 22 glaucomatous eyes, corresponding to 40% of the pretreatment pressure levels. With both solutions a reduction of the first day's response was noted after repeated administration of timolol. In all patients tested timolol was tolerated well subjectively and objectively without any side effects. Timolol did not affect blood pressure or pulse rate. Tear production was not reduced after topical application of timolol. Pupillary diameter and facility of outflow were not changed significantly under therapy. It is concluded, that timolol acts primarily by reduction of aqueous inflow. The advantages of timolol as antiglaucomatous drug not affecting visual functions like miotics are discussed.
使用0.1%和0.5%的溶液,在两组开角型青光眼患者中测试了β-肾上腺素能阻滞剂噻吗洛尔滴眼液的眼压反应。0.5%浓度的溶液使39只青光眼眼的眼压平均降低了13毫米汞柱,相当于治疗前眼压水平的46%。0.1%浓度的溶液使22只青光眼眼的眼压平均降低了11.5毫米汞柱,相当于治疗前眼压水平的40%。重复使用噻吗洛尔后,两种溶液第一天的反应均有所降低。在所有接受测试的患者中,噻吗洛尔在主观和客观上耐受性良好,无任何副作用。噻吗洛尔不影响血压或脉搏率。局部应用噻吗洛尔后泪液分泌未减少。治疗期间瞳孔直径和房水流出易度无明显变化。得出结论,噻吗洛尔主要通过减少房水生成起作用。讨论了噻吗洛尔作为抗青光眼药物不影响像缩瞳剂那样的视觉功能的优点。